0000950170-24-001204.txt : 20240103 0000950170-24-001204.hdr.sgml : 20240103 20240103173410 ACCESSION NUMBER: 0000950170-24-001204 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240101 FILED AS OF DATE: 20240103 DATE AS OF CHANGE: 20240103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lebwohl David CENTRAL INDEX KEY: 0001810882 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37766 FILM NUMBER: 24508370 MAIL ADDRESS: STREET 1: C/O INTELLIA THERAPEUTICS, INC. STREET 2: 40 ERIE STREET, SUITE 130 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Intellia Therapeutics, Inc. CENTRAL INDEX KEY: 0001652130 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 364785571 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 40 ERIE STREET STREET 2: SUITE 130 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-285-6200 MAIL ADDRESS: STREET 1: 40 ERIE STREET STREET 2: SUITE 130 CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 ownership.xml 4 X0508 4 2024-01-01 0001652130 Intellia Therapeutics, Inc. NTLA 0001810882 Lebwohl David C/O INTELLIA THERAPEUTICS, INC. 40 ERIE STREET; SUITE 130 CAMBRIDGE MA 02139 false true false false EVP, Chief Medical Officer false Common Stock 2024-01-01 4 M false 3187 A 60215 D Restricted Stock Unit 2024-01-01 4 M false 3187 0 D 2024-01-01 2031-03-02 Common Stock 3187 3189 D Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Includes 360 and 307 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2023 and December 31, 2023, respectively. On March 3, 2021, the reporting person was granted 12,750 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter. James Basta, attorney-in-fact 2024-01-03